Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November
Caladrius Biosciences (Nasdaq: CLBS) announced its participation in three virtual investor conferences in November 2020, showcasing its commitment to cellular therapies aimed at reversing disease. The conferences include the LSX Virtual Inv€$tival Showcase from November 11-16, the Jefferies Virtual London Healthcare Conference from November 17-19, and the A.G.P. Virtual Healthcare Symposium on November 19. Management will hold one-on-one meetings at these events to discuss their innovative therapies, including HONEDRA® and CLBS14. For inquiries, contact investor relations directly.
- None.
- None.
BASKING RIDGE, N.J. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020.
November 11-16, 2020
LSX Virtual Inv€$tival Showcase
November 17-19, 2020
Jefferies Virtual London Healthcare Conference
November 19, 2020
A.G.P. Virtual Healthcare Symposium
Management will participate in one-on-one meetings throughout each conference. To inquire about arranging a virtual meeting with management, please contact John Menditto at jmenditto@caladrius.com.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of a recently completed positive Phase 2a clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients. For more information on the company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
FAQ
What upcoming conferences is Caladrius Biosciences (CLBS) attending?
How can I arrange a meeting with Caladrius management during the conferences?
What products are highlighted by Caladrius Biosciences (CLBS) in their latest PR?
What is the SAKIGAKE designation mentioned in relation to CLBS products?
What is the focus of Caladrius Biosciences' therapies?
